Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors

By Fujisaka Yasuhito   Yamada Yasuhide   Yamamoto Noboru   Shimizu Toshio   Fujiwara Yutaka   Yamada Kazuhiko   Tamura Tomohide   Watanabe Hiroyuki   Sun Yu-Nien   Bass Michael   Seki Mitsuo  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 5, 2010-10 ,pp. : 935-943

Springer Publishing Company

Access to resources Recommend Favorite

Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors

By Doi Toshihiko   Ohtsu Atsushi   Fuse Nozomu   Yoshino Takayuki   Tahara Makoto   Shibayama Kazuhiro   Takubo Takatoshi   Weinreich David  

Cancer Chemotherapy and Pharmacology, Vol. 71, Iss. 1, 2013-01 ,pp. : 227-235

Springer Publishing Company

Access to resources Recommend Favorite

Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review

By                                                          

International Journal of Oncology, Vol. 44, Iss. 1, 2014-01 ,pp. : 5-16

Spandidos Publications

Access to resources Recommend Favorite

Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer

By Claret Laurent   Lu Jian-Feng   Sun Yu-Nien   Bruno René  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 6, 2010-11 ,pp. : 1141-1149

Springer Publishing Company

Access to resources Recommend Favorite

Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors

By Tran Hai   Blumenschein George   Lu Charles   Meyers Christina   Papadimitrakopoulou Vali   Fossella Frank   Zinner Ralph   Madden Timothy   Smythe Lori   Puduvalli Vinay   Munden Reggie   Truong Mylene   Herbst Roy  

Cancer Chemotherapy and Pharmacology, Vol. 54, Iss. 4, 2004-10 ,pp. : 308-314

Springer Publishing Company

Access to resources Recommend Favorite